Literature DB >> 16818619

Genetic background controls tumor development in PTEN-deficient mice.

Dan Freeman1, Ralf Lesche, Nathalie Kertesz, Shungyou Wang, Gang Li, Jing Gao, Matthias Groszer, Hilda Martinez-Diaz, Nora Rozengurt, George Thomas, Xin Liu, Hong Wu.   

Abstract

PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten(Delta5)) or promoter to exon 3 (Pten(-)) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16818619     DOI: 10.1158/0008-5472.CAN-05-4143

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  53 in total

1.  Embryonic epithelial Pten deletion through Nkx2.1-cre leads to thyroid tumorigenesis in a strain-dependent manner.

Authors:  Saverio Bellusci; Parviz Minoo; Caterina Tiozzo; Soula Danopoulos; Maria Lavarreda-Pearce; Sheryl Baptista; Radka Varimezova; Denise Al Alam; David Warburton; Rehan Virender; Stijn De Langhe; Antonio Di Cristofano
Journal:  Endocr Relat Cancer       Date:  2012-04-10       Impact factor: 5.678

2.  Dietary energy balance modulates prostate cancer progression in Hi-Myc mice.

Authors:  Jorge Blando; Tricia Moore; Stephen Hursting; Guiyu Jiang; Achinto Saha; Linda Beltran; Jianjun Shen; John Repass; Sara Strom; John DiGiovanni
Journal:  Cancer Prev Res (Phila)       Date:  2011-09-27

3.  FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis.

Authors:  Ji-Hye Paik; Ramya Kollipara; Gerald Chu; Hongkai Ji; Yonghong Xiao; Zhihu Ding; Lili Miao; Zuzana Tothova; James W Horner; Daniel R Carrasco; Shan Jiang; D Gary Gilliland; Lynda Chin; Wing H Wong; Diego H Castrillon; Ronald A DePinho
Journal:  Cell       Date:  2007-01-26       Impact factor: 41.582

4.  δ-Tocopherol inhibits the development of prostate adenocarcinoma in prostate specific Pten-/- mice.

Authors:  Hong Wang; Xu Yang; Anna Liu; Guocan Wang; Maarten C Bosland; Chung S Yang
Journal:  Carcinogenesis       Date:  2018-02-09       Impact factor: 4.944

5.  Pten regulates collective cell migration during specification of the anterior-posterior axis of the mouse embryo.

Authors:  Joshua Bloomekatz; Joaquim Grego-Bessa; Isabelle Migeotte; Kathryn V Anderson
Journal:  Dev Biol       Date:  2012-02-11       Impact factor: 3.582

6.  Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells.

Authors:  Yun Lu; J Michael Thomson; Ho Yuen Frank Wong; Scott M Hammond; Brigid L M Hogan
Journal:  Dev Biol       Date:  2007-08-09       Impact factor: 3.582

7.  Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention.

Authors:  Shidong Jia; Xueliang Gao; Sang Hyun Lee; Sauveur-Michel Maira; Xiaoqiu Wu; Edward C Stack; Sabina Signoretti; Massimo Loda; Jean J Zhao; Thomas M Roberts
Journal:  Cancer Discov       Date:  2012-12-20       Impact factor: 39.397

Review 8.  Oncogenic PTEN functions and models in T-cell malignancies.

Authors:  M Tesio; A Trinquand; E Macintyre; V Asnafi
Journal:  Oncogene       Date:  2015-11-30       Impact factor: 9.867

9.  Brca2 and Trp53 deficiency cooperate in the progression of mouse prostate tumourigenesis.

Authors:  Jeffrey C Francis; Afshan McCarthy; Martin K Thomsen; Alan Ashworth; Amanda Swain
Journal:  PLoS Genet       Date:  2010-06-24       Impact factor: 5.917

10.  Sprouty genes function in suppression of prostate tumorigenesis.

Authors:  Jennifer L Schutzman; Gail R Martin
Journal:  Proc Natl Acad Sci U S A       Date:  2012-11-13       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.